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Abstract
Aim: Several multigene expression-based tests offering prognostic and predictive information in hormone-receptor positive
early breast cancer were established during the last years. These tests provide prognostic information on distant recurrences
and can serve as an aid in therapy decisions. We analyzed the recently validated reverse-transcription-quantitative-real-time
PCR-based multigene-expression Endopredict (EP)-test on 34 hormone-receptor positive breast-cancer cases and compared
the EP scores with the Oncotype DX Recurrence-scores (RS) obtained from the same cancer samples.
Methods: Formalin-fixed, paraffin-embedded invasive breast-cancer tissues from 34 patients were analyzed by the EP-test.
Representative tumor blocks were analyzed with Oncotype DX prior to this study. Tumor tissue was removed from
unstained slides, total-RNA was isolated and EP-analysis was performed blinded to Oncotype DX results.
Results: Extraction of sufficient amounts of RNA and generation of valid EP-scores were possible for all 34 samples. EP
classified 11 patients as low-risk and 23 patients as high-risk. RS Score defined 15 patients as low-risk, 10 patients as
intermediate-risk in and 9 patients as high-risk. Major-discrepancy occurred in 6 of 34 cases (18%): Low-risk RS was classified
as high-risk by EP in 6 cases. Combining the RS intermediate-risk and high-risk groups to a common group, the concordance
between both tests was 76%. Correlation between continuous EP and RS-scores was moderate (Pearson-coefficient: 0.65
(p,0.01).
Conclusion: We observed a significant but moderate concordance (76%) and moderate correlation (0.65) between RS and
EP Score. Differences in results can be explained by different weighting of biological motives covered by the two tests.
Further studies are needed to explore the clinical relevance of discrepant test results with respect of outcome.
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Introduction
Biomarkers in breast cancer contribute essentially to adjuvant
and preoperative therapy assessment. Additionally to conventional
prognostic factors as tumor-size, grading or nodal status, treatment
decisions include the three established predictive biomarkers as
estrogen (ER) and progesterone (PR) receptors and the HER2
status [1,2,3]. Prognostic factors provide information on the
likelihood of cancer progression in untreated patients, whereas
predictive factors carry information on the probability of therapy
response [3,4]. Multigene assays have become more widely used to
prognosticate breast cancer clinical course and assist in the
decision making for or against adjuvant chemotherapy
[5,6,7,8,9,10]. The benefit of chemotherapy in addition to regular
hormonal therapy remains a subject of dispute in hormone
receptor positive early breast cancer [3,11,12]. Several tests were
developed in the recent years measuring the expression profile of
cancer-related genes and providing prognostic information on
disease-free and overall survival. The Netherlands Cancer Institute
in Amsterdam launched Mammaprint, a 70-gene assay in 2002.
The genetic signature of Mammaprint predicted metastasis free
survival and overall survival in a validation study on 295 breast
cancer patients [13,14]. Oncotype DX, a 21-gene assay was first
tested in clinical trials in 2004. It is able to quantify the likelihood
of distant recurrence and the probability of response to
chemotherapy in early breast cancer [11,15,16]. The Recurrence
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Score was validated in the NSABP B-14 trial in 2004 on 645
patients. The NSABP B-20 trial in 2006 analyzed 651 patients and
validated the benefit of additional chemotherapy in patients with
high Recurrence Score [15,16]. Since the initiation of Mamma-
print and Oncotype DX, additional multigene tests (e.g. Breast
Cancer Index, Rotterdam, Invasiveness gene signature, PAM5)
were developed, which are being either commercially available or
currently under clinical investigation [17]. These gene assays,
either reverse transcription-quantitative real-time PCR (RT-
qPCR)- or microarray-based increasingly meet clinical attention,
as they represent potential additional tools to conventional
pathological prognostic factors and to established international
oncological guidelines [17]. In 2011, a new 12-gene test, the
EndoPredict assay was launched. It was validated independently in
patients from two large randomized phase III trials (Austrian
Breast and Colorectal Cancer Study Group (ABCSG)-6: n= 378,
ABCSG-8: n= 1324) [18]. The EndoPredict (EP) risk score
provided additional prognostic information to the risk of distant
recurrence in hormone receptor positive, nodal negative breast
cancer patients. The EPclin score which is the EP score combined
with the clinico-pathological parameters tumor size and nodal
status was the first RNA-based prognostic test for breast cancer to
outperform all conventional clinic-pathologic risk factors alone or
in combination with each other [18,19]. The performance of the
EndoPredict assay in decentralized testing using formalin-fixed,
paraffin-embedded (FFPE) tumor tissue was successfully shown in
seven European pathology institutions reaching 100% concor-
dance between the different sites [19].
In this retrospective study, we addressed to investigate the
concordance of EndoPredict scores and the Oncotype DX
Recurrence Scores in 34 hormone receptor positive breast cancer
patients.
Materials and Methods
Patients’ Characteristics
34 patients with invasive breast carcinoma were selected for this
study (18 cases from the Institute of Surgical Pathology, University
Hospital Zurich, Switzerland, 10 cases from the Institute of
Pathology, University Hospital Heidelberg, Germany and 6 cases
Table 1. Summary of clinical data.
n=34
Age (years) ,40 3
.40 31
Tumor size pT1b (0.5 to 1 cm) 5
pT1c (.1 to 2 cm) 19
pT2 (.2 to 5 cm) 8
pT3 (.5 cm) 2
Nodal status negative 21
positive 13
Grading 1 2
2 21
3 11
ER status positive 34
Negative –
PR status positive 31
negative 3
HER2 status negative 33
positive 1
ER: estrogen receptors, PR: progesterone receptors, NA: not available.
doi:10.1371/journal.pone.0058483.t001
Figure 1. Analytical comparison of Recurrence Score with EndoPredict Score (A) and EPclin Score (B). r = Pearson coefficient.
doi:10.1371/journal.pone.0058483.g001
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from the Pathology Institute Enge Zu¨rich Switzerland). The time
of diagnoses was between 2008–2012.
All tumors were estrogen receptor and in the majority also
progesterone receptor positive. On histology 28 tumors corre-
sponded to invasive ductal carcinoma (82%), three to invasive
lobular carcinoma (9%) and three tumors were diagnosed as a
mixed invasive carcinoma with ductal, lobular and squamous
components (9%).
Clinico-pathological data of the tumors are summarized in
Table 1.
The study was designated and approved as a quality control
study by the Review Board of the Institute of Surgical Pathology
(project Nr. 285). The review board specifically waived from the
need of an approval of the cantonal ethical committee. According
to the Federal Swiss Law for research and as required by the
ethical committee of Canton Zurich, no additional ethical
committee approval was necessary, as the study was designated
as a quality control study and all tissue samples were analyzed in a
completely anonymized way.
Immunohistochemistry for ER/PR/HER2 and Ki-67
Hormone receptor status (in all cases), HER2 status (in 16 cases,
from Heidelberg and Pathology Enge) and proliferation fraction
(in 33 cases) were determined during routine histological
diagnostics using commercial antibodies following the manufac-
tures’ recommendations on the Ventana Benchmark and Leica
Bond autostainers. Primary antibodies were detected using the
iVIEW DAB detection kit and the signal was enhanced using the
amplification kit. Following markers and dilutions were used:
HER2 (4B5 Ventana Basel Switzerland) (MIB-1 (Ki-67) (DAKO
Denmark, Glostrup, dilution 1:20), estrogen receptors (6F11,
Ventana Basel, Switzerland, dispenser), progesterone receptor
(1A6, Ventana, Basel Switzerland, dispenser) as described
previously [20]. Cut-off for positive ER/PR status was set as 1%
of positively stained nuclei. HER2 immunohistochemstry was
scored as described in the ASCO guidelines [21].
Fluorescence in situ Hybridization (FISH) for HER2
HER2 status was determined within on the primary tumor
using FISH only-methodology in 18 of 34 cases (cases from
Zurich, University Hospital). All procedures for the FISH analyses
were carried out by following the recommended protocol of the
manufacturers using a dual fluorescence kit (PathVysionTM, Vysis,
Abbott AG, Diagnostic Division Baar, Switzerland).The reactions
were evaluated using an Olympus computer guided fluorescence
microscope (BX61, Olympus Schweiz AG, Volketswil, Switzer-
land). FISH testing was evaluated in reference to the ASCO
guidelines [21].
Cut-off for positive HER2 status was set as HER2/CEP17 ratio
$2.2.
Tissue Preparation for Oncotype DX Tests
Upon request of the oncologists in charge, samples were
submitted to Genomic Health (Redwood City, CA) for Oncotype
DX testing for breast cancer prior to this study. For this assay, one
representative paraffin block was chosen from the cases, contain-
ing the largest amount of invasive tumor cells on the hematoxyline
& eosin (H&E) slides. The amount of tumor cells was at least 10%
of the H&E slide. According to the pathology guidelines of
Oncotype DX, 15 unstained serial slides of 4 micrometer thickness
per tumor block were freshly cut from the paraffin blocks and
submitted for the assay. Recurrence Score were assessed by
Genomic Health in all patients. RNA-based ER, PR and HER2
status were available in 33 of 34 patients.
Tissue Preparation and RNA Isolation for EndoPredict
Tests
The same paraffin blocks assessed by Oncotype DX were used
for EndoPredict. Slides and sections for the EndoPredict assay for
this study contained immediately adjacent tissues to those
previously submitted to Genomic Health. The amount of invasive
carcinoma tissue was at least 10% of the whole section surface in
each case.
One H&E section and three adjacent serial unstained slides
(4 mm) were cut from each paraffin block. On the H&E slide, the
area of the invasive tumor cells was identified under light
microscope and marked with ink. The same area was also marked
on the unstained slides. Tumor tissue was scraped from the
unstained slides into a plastic tube using a scalpel permitting the
analysis of almost 100% of invasive tumor tissue by the
EndoPredict test. Total RNA was extracted using a silica-coated
magnetic bead-based method as previously described RNA was
eluted with 100 mL elution buffer and subjected to DNase
digestion as described to get DNA-free total RNA.
Unstained slides and H&E sections for both Oncotype DX and
EndoPredict analysis were prepared in an identical way in the
Institute of Surgical Pathology, University Hospital Zurich.
Table 2. Comparison of EP score and Recurrence score (RS).
n=34 Recurrence score (RS) (three tiered)
Low risk Intermediate risk High risk
EP score Low risk 9 (26%) 2 (6%) 0 (0%)
High risk 6 (18%) 8 (24%) 9 (26%)
RS in three tiered system.
doi:10.1371/journal.pone.0058483.t002
Table 3. Comparison of EP score and Recurrence score (RS).
RS in two tiered system: low vs. intermediate+high risk.
n=34 Recurrence score (RS) (two tiered)
Low risk High+Intermediate risk
EP score Low risk 9 (26%) 2 (6%)
High risk 6 (18%) 17 (50%)
doi:10.1371/journal.pone.0058483.t003
Table 4. Comparison of EPclin score and Recurrence score
(RS). RS in three tiered system.
n=34 Recurrence score (RS) (three tired)
Low risk Intermediate risk High risk
EPclin score Low risk 11 (32%) 5 (15%) 3 (9%)
High risk 4 (11%) 5 (15%) 6 (18%)
doi:10.1371/journal.pone.0058483.t004
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Performance of EndoPredict Test
The EndoPredict assay (Sividon Diagnostics, Cologne, Ger-
many) was performed as published previously [19]. In brief,
expression of 8 genes–of-interest (AZGP1, BIRC5, DHCR7, IL6ST,
MGP, RBBP8, STC2, UBE2C) and three reference genes (CALM2,
OAZ1, RPL37A) as well as the amount of residual genomic DNA
(HBB) were assessed by one-step RT-qPCR using the SuperScript
III PLATINUM One-Step Quantitative RT-PCR System with
ROX (Invitrogen, Karlsruhe, Germany) according to manufac-
turer’s instructions in a VERSANTH kPCR Molecular System
(Siemens Healthcare Diagnostics). Sequences of primers and
FAM/TAMRA-labeled probes were published previously [18]. EP
and EPclin scores as well as classification into low or high risk of
distant metastasis were calculated from analytical PCR results,
tumor size and nodal status using a web-based implementation as
described previously [19]. RT-qPCR analyses and calculations of
EP and EPclin scores were performed by laboratory scientists in
Sividon Diagnostics blinded to the results from the Oncotype DX
tests. The scores and risk groups for each patient were
subsequently transferred for analysis to one pathologist (Z.V).
Extraction of a sufficient amount of RNA and generation of a valid
EP score was possible for all 34 study samples.
Statistics
Statistical analysis was performed using the Pearson’s correla-
tion coefficient. Signifcance was defined as p,0.05.
Results
Oncotype DX Recurrence Score (RS)
Results of the individual patients were provided by Genomic
Health to the submitting clinicians (A.T, C.T) and to the
pathologists (A.N, Z.V, P.S, F.F, A.H).
Recurrence Score (RS) revealed low risk in 15 patients,
intermediate risk in 10 patients and high risk in 9 patients.
EndoPredict Test
The EndoPredict test results in an EP risk score and an EPclin
score.
Table 5. Comparison of EPclin score and Recurrence score
(RS). RS in two tiered system: low vs. intermediate+high risk.
n=34 Recurrence score (RS) (two tiered)
Low risk High+Intermediate risk
EPclin score Low risk 11 (32%) 8 (24%)
High risk 4 (12%) 11 (32%)
doi:10.1371/journal.pone.0058483.t005
Figure 2. Analytical comparison of continuous Ki67 values with Recurrence Score (A) and EndoPredict Score (B). r =Pearson
coefficient.
doi:10.1371/journal.pone.0058483.g002
Table 6. Comparison of ER/PR/HER2 status with Oncotype DX
assay and conventional methodology (Immunohistochemistry
and fluorescence in situ hybridization ‘FISH’ testing).
n=33 Oncotype DX testing
Conventional metholodogy positive negative equivocal
ER positive 33 (100%) 33 (100%) – –
negative – – – –
PR positive 30 (91%) 26 (79%) 4 (12%) –
negative 3 (9%) 1 (3%) 2 (6%) –
HER2 positive 1 (3%) 0 1 (3%) –
negative 32 (97%) – 31 (94%) 1 (3%)
equivocal – – – –
In one case results of Oncotype DX for ER/PR/HER2 status were not available.
doi:10.1371/journal.pone.0058483.t006
Breast Cancer, Gene Test, EndoPredict, Oncotype DX
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According to the EP risk score 11 patients were classified as low
risk and 23 patients as high risk.
The EPclin score (combining EP risk score with tumor size and
nodal status) re-classified 8 of the 23 EP high risk patients into the
low risk group resulting in 19 patients with low and 15 patients
with high risk of distant metastasis.
Correlation and Concordance between Recurrence Score
and EP Risk Score
Comparing EP risk scores with Recurrence Score, a moderate
(yet significant) correlation was found as reflected by a Pearson
coefficient of 0.65 (p,0.01). Nine of 15 of samples classified as low
risk by the Recurrence Score were also low risk by EP score (60%).
Nine of nine RS high risk samples were also EP high risk (100%).
By combining the Oncotype DX intermediate risk and high risk
groups to one high risk group, the concordance of classification in
low or high risk between both tests was found in 26 of 34 cases
(76%).
The results of RS and EP scores are summarized in Tables 2,
3 and Fig. 1A.
Correlation and Concordance between Recurrence Score
and EPclin Score
Comparing the combined molecular-clinicopathologic EPclin
score with the Recurrence Score the correlation was substantially
smaller in comparison with the correlation between RS and EP
scores. Pearson coefficient was 0.45 (p= 0.01).
Eleven of 15 samples classified as low risk by the Recurrence
Score were also low risk by EPclin score (73%). Six of nine RS
high risk samples were EPclin high risk (66%). Combining the
Oncotype DX intermediate risk and high risk groups to one high
risk group, the concordance of classification in low or high risk
between both tests was detected in 22 of 34 cases (65%). The
results of RS and EPclin score are summarized in Tables 4, 5
and Fig. 1B.
Correlation and Concordance of Ki-67 to EP Score, EPclin
Score and RS
We could find a statistically significant but moderate correlation
between the two molecular scores and proliferation index. No
significant correlation was observed between the EPclin score and
Ki-67. (Pearson coefficient varied as follows: to EP: 0.55
(p,0.0001), to EPclin: 0.24 (p= 0.16), to RS: 0.56 (p,0.0001).
Results of continuous Ki-67 values and risk classes are
illustrated in Fig. 2.
Comparison of ER/PR/HER2 Status with Conventional
Morphology and Oncotype DX Assay
We detected a high concordance in hormone receptor and HER2
status between conventional morphology and Oncotype DX
testing.
33 of 33 patients were positive for ER with immunohistochem-
ical (IHC) analysis and with Oncotype DX assay (100%).
28 of 33 patients had identical PR status with both method-
ologies (85%). Three patients had PR positive cells in approxi-
mately 20%–30% of the tumor cells on immunohistochemistry,
which were assessed as negative with Oncotype DX. The re-
analysis of the immunohistochemical PR reactions confirmed
small amount of positively stained nuclei.
31 of 33 patients had matching HER2 status with both methods
(94%). One patient had a negative HER2 status by FISH which
was assessed as equivocal with Oncotype DX. Another patient had
HER2 amplification by FISH, which was negative by Oncotype
DX. The FISH HER2 reaction was re-analyzed again and the
amplification status could be confirmed.
Results of hormone receptor/HER2 status and RS are
summarized in Table 6.
Discussion
In this study, we investigated retrospectively the correlation
between EndoPredict scores and Oncotype DX Recurrence
Scores using 34 hormone receptor positive breast cancer samples.
Importantly, EndoPredict score showed a significant but only
moderate correlation with the Recurrence Scores obtained by
Oncotype DX testing. We found a moderate concordance of
results regarding classification into risk groups between the two
assays (reaching 76%) (two tiered). A major discrepancy between
the two gene signatures was detected in 6 of 34 patients (18%)
(three tiered).
The discrepancy and moderate correlation of the two molecular
scores EP and RS might be due to differences in weighting of main
biological motives covered by the genes included in the test
algorithms such as proliferation or ER signaling. Some differences
might be explained by the coverage of other motives, e.g. cell
adhesion, invasion, or DNA repair [11,18]. Interestingly, an even
smaller agreement is achieved, if the molecular RS is compared to
the combined molecular-clinico-pathological EPclin score as
opposed to the molecular EP score. This lower agreement is likely
caused by the fact that the EPclin score considers additional
prognostic information that may not be reflected by the tumor’s
RNA expression. Following the EPclin-based classification into
low or high risk of metastasis would spare 19 of 34 (56%) patients a
cytotoxic chemotherapy in the light of an estimated 10-years
distant metastasis-free survival of 96% of EPclin low risk patients
in the two clinical validation studies [18]. Nevertheless, further
prospective clinical trials are needed to validate these results.
Another multi-gene test, Mammaprint, was previously been
compared with Oncotype DX [22]. In this analysis, a higher
concordance (81%) between high and intermediate risk groups
from the Oncotype DX and poor prognostic groups of
Mammaprint tests were shown. Our study showed a weaker
concordance of 76% between EP sore and high/intermediate risk
groups assessed by Oncotype DX.
Together, different multigene may result in different treatment
recommendation for individual patients. One limitation of
previous studies is the sample size. Further analyses with longer
patient survival data are necessary for the re-validation of these
results.
Oncotype DX is a RT-qPCR based 21-gene assay using RNA
from FFPE tissue, comprising 16 cancer genes primarily related to
tumor proliferation [11,16]. This test is performed in a central
reference laboratory. The NSABP B14 clinical trial validated, that
patients with low RS developed significantly lower distant
metastases than those patients with high RS [11]. Analysis on
prognostic value of RS as to distant metastases in early hormone
receptor positive breast cancer has been the subject of several
further clinical studies since the NSABP B14 trial chemotherapy
[6,7,8,9,10,11,12,17].
The consecutive clinical trial, the NSABP B20 validated the
predictive value of RS on additional chemotherapy on hormone
receptor positive nodal negative breast cancer patients [15]. Data
on 651 enrolled patients revealed that patients with high RS
exhibited improved response to chemotherapy [10,15]. On the
other hand, it was also shown that patients with low risk RS did
not benefit from additional chemotherapy [10,15]. Response on
Breast Cancer, Gene Test, EndoPredict, Oncotype DX
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chemotherapy in intermediate risk RS is currently being
investigated in the ongoing TAILORx clinical trial [10].
The EndoPredict assay is an RT-qPCR-based 12-gene test
using RNA from FFPE tissue, specifically validated in two clinical
studies for recurrence prediction in hormone receptor positive,
HER2 negative, nodal negative and positive breast cancer treated
with adjuvant hormonal therapy alone [18]. The EP score
provided significant prognostic information in addition to
conventional prognostic clinico-pathological parameters such as
tumor size, nodal status, grading, quantitative ER and Ki-67 as
well as Adjuvant!Online [18]. Moreover, the combination of the
molecular EP score with tumor size and nodal status to the
comprehensive molecular-clinico-pathological EPclin score out-
performed the established prognostic parameters in these two
patients cohort [18]. Recently, it could be shown in a proficiency
testing program including seven different pathological institutes
that EndoPredict can be reliably performed in a decentralized
setting in molecular pathological laboratories without the require-
ment of a reference lab [19].
In contrast to EndoPredict, Oncotype DX assay includes an
RT-qPCR based determination of hormone receptor and HER2
gene amplification. This fact prompted several previous studies to
compare expression profile of these parameters. Excellent
correlation with 100% concordance has been reported by
O’Connor et al. in a series on 80 breast cancer samples [23].
We found high concordance in ER/PR/HER2 status between
Oncotype DX assay and established FISH or IHC assays, also
regarded as a ‘‘gold standard’’. There were only two discrepant
cases for the HER2 status and six cases for progesterone receptors
with no discrepant cases for estrogen receptors. This observation is
in line with occasional false negative HER2 results reported as part
of the Recurrence Score [24]. Importantly, Geradts et al. detected
discrepancies in hormone receptor and HER2 status determined
by the conventional assays (IHC and/or FISH) and RT-PCR
methodologies. There was only 56 to 66% categorical concor-
dance [25]. A similar result was found in a further study showing
33% of HER2 IHC-positive samples to be HER2 negative in RT-
qPCR whereas the concordance of both methods in HER2 IHC-
negative samples was 95% [26]. It is not clear at this time, which
methodology is superior in respect of predictive power. This needs
to be addressed in future prospective trials. In current clinical
practice, such discrepancies in the most important predictive
breast cancer biomarkers are significantly hampering the treat-
ment decision making process. Interestingly, a strong correlation
between morphological parameter (especially histological tumor
grading) and Recurrences Score was established in a few previous
studies [27,28]. The classification into two-tiered (low and high)
risk categories with EndoPredict assay can possibly yield in clearer
separation of intermediate risk patients.
Concordance between Recurrence score and other prognostic
assays or clinico-pathological parameter is of interest in clinical
decision making.
Significant linear correlation between proliferation index (Ki-
67) and Recurrence Score was established previously in hormone
receptor positive breast cancer. These data recommend the
potential use of more cost effective immunohistochemical assess-
ment of proliferation fraction rather than ordering highly
expensive Oncotype DX testing [29,30]. Another study by Tang
et al. found good independent prognostic information in tamox-
ifen treated patients when Recurrence Score and individual
clinico-pathological parameter were analyzed together [31].
Interestingly, combining Adjuvant! Online recommendation with
Recurrence Score did not provide better prognostic benefit in their
analysis [31]. Recently, a good agreement of prognostic risk
assignment between the gene expression-based ‘‘intrinsic’’ subtype
test PAM50 and Oncotype DX was described [32].
Determining predictive markers with routine pathology assess-
ment and using standardized reproducible criteria for morpho-
logical parameter (as grading, tumor size) represent a much less
expensive alternative to multigene expression assays [10,22]. It has
been suggested that routine pathology markers are probably as
reliable as genetic signatures at the current time, especially if
combined mathematically [10,22,33]. We could detect significant
but moderate correlation between continuous proliferation index
(Ki-67) and RS and EP scores. This is at least partially due to the
lack of standardization in assessing the Ki-67 index in breast
cancer [34].
A considerable percentage of women diagnosed with breast
cancer are aware of the valuable information multigene tests may
add to their immediate therapeutic options [35,36,37]. The impact
of Oncotype DX testing is clearly reflected on altered recommen-
dations or therapy decision in view of RS, which reportedly varies
from 19 to 44% of the studied patients [38,39,40,41].
In conclusion, our data show moderate concordance between
EndoPredict Score and Oncotyope DX results on individual
patients. In the light of previous clinical and analytical validation
data EP bears the promise to be an additional tool for
decentralized multigene testing by local pathology with the
advantage of the inclusion of important clinic-pathological data
as nodal status. Further clinical studies are needed to compare
both tests with regard to prediction of early and late distant
metastasis, chemotherapy benefit and clinical outcome.
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